Cocrystal Pharma Q1 net loss $5.2M; progresses COVID-19/flu trials; raises $4M

Cocrystal Pharma, Inc.

2024-Q1 EPS reported -$0.64

Net loss of $5.2M ($0.64/share) vs $4.2M ($0.52) in Q1 2022; R&D expense $3.9M (up from $2.9M).
Cash of $34.0M at March 31, 2023; working capital $33.8M; 8.1M shares outstanding.
Raised $4M via private placement from directors Dr. Phillip Frost and Fred Hassan; Hassan joined board.
Submitted application for Phase 1 trial of COVID-19 oral protease inhibitor CDI-988 in Australia.
Expects to start Phase 2a human challenge study for influenza A candidate CC-42344 in H2 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Cocrystal Pharma, Inc. reported financial results for three months ended March 31, 2023.

Period: three months ended March 31, 2023
Result: reported results

Exact text from the filing

On May 15, 2023, Cocrystal Pharma, Inc. (the “Company”) issued a press release announcing its results of operations for the fiscal quarter ended March 31, 2023.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Cocrystal Pharma, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-016922

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.